

Respirair and Dechra - US Veterinary Anaesthesia Partnership

Respirair Global is proud and excited to confirm the launch of a game changing strategic alliance with Dechra in the USA for Isoflurane and Sevoflurane veterinary vaporizers and anaesthesia accessories.

“Innovation and collaboration are at the heart of this partnership”, said Neil Redmayne, CEO Respirair. “We are striving to raise the bar on quality, service, sustainability and value by bringing high quality, affordable products, with an innovative 360° wraparound service package to the US veterinary market”.

By supplying its market leading, precision engineered vaporisers, trolleys and accessories, in conjunction with Dechra’s isoflurane and sevoflurane general inhalation anaesthetic agents, the collaboration seeks to create a powerful new force in veterinary anaesthesia coupled with proven, trusted and peerless quality delivery technologies.

The Respirair vaporiser comes with an industry beating warranty of 6 years; backed up by a Respirair Global service center. Quality, pricing and service are the keys - the Respirair vaporiser offers best in class thermal dynamics, a coating process that ensures a lifetime of anti-corrosion protection, thermostats that are more durable than previously available, and are all individually tested to significantly tighter tolerances than industry standard. All product variants are available in all fitting and filler options.

Mike Eldred, President of Dechra North American stated, “we are pleased to have partnered with Respirair Global to provide veterinarians with high quality and affordable anaesthesia equipment, along with our low-cost general anaesthetics agents, isoflurane and sevoflurane. This partnership further strengthens our position as a leader in the veterinary surgical suite market segment.”

About Respirair Global:

Respirair Global is creating 2.0 platform built on the heritage, technology and legacy of an established and longstanding medical device and anaesthesia machine manufacturer. The business recently announced new appointees to its leadership team and clinical advisory group. The appointments include a new MBA qualified Managing Director – with over 30 years of engineering and manufacturing experience and success – ranging from SME’s to globals in the engineering/tech space. The business has also appointed a new head of Business Strategy; Steve Street – again, with an impressive pedigree and track record in business, product and service innovation, NPD, strategic partnering and business governance. Respirair Global has embarked on a programme of business growth and development – partly organic and partly via alliances and targeted acquisitions.

About Dechra:

Dechra’s companion animal portfolio focuses on endocrinology, oncology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl[®] Capsules (trilostane), Zycortal[®] Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole[®] Coated Tablets (methimazole), Vetrudent[™], the Vetivex[®] line of parenteral fluids, Isoflurane, USP Inhalant Anesthetic, Sevoflurane, USP Inhalant Anesthetic, and Phycox[®] joint health supplements. Osurnia[®] (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto[®], MiconHex+Triz[®], MalAcetic[®], and oral anti-infective product lines, including Marboquin[®] (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. The addition of Mirataz[®] (mirtazapine transdermal ointment), Porus[®] One, and Redonyl[®] Ultra Feline to the companion animal line supports the underserved feline market. Dechra also recently acquired the worldwide rights to the novel drug Laverdia[™]-CA1 (verdinexor) for dogs. Our equine portfolio includes Osphos[®] (clodronate injection), Orthokine[®] vet irap 10 and 60, Osteokine[®] (PRP), Equidone[®] (domperidone) Gel, Zimeta[®] (dipyrone injection), ProVet APC[™] (Autologous Platelet Concentrate) system, Rompun[®] (xylazine injection), Butorphanol Tartrate Injection, Isoflurane, USP Inhalant Anesthetic, SucroMate[®] Equine (deslorelin acetate), and the Phycox[®] EQ joint health supplements.

Contact:

Mike Eldred
President, North American Operations
Dechra Veterinary Products
mike.eldred@Dechra.com

Neil Redmayne
CEO
Respirair Global
neil@respirairglobal.com